Pasithea Therapeutics (KTTA)CEO bought ~$25K

~$25K

Approx. value · 33K sh @ $0.75

73K

Holds after · shares reported

Traded

Nov 28, 2025

Filed

Dec 1, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 24, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 24, 2025, the Board of Directors (the “Board”) of Pasithea Therapeutics Corp. (the “Company”) approved the following compensation arrangements for the Company’s executive officers and directors.”
2. Nov 28, 2025 · this disclosureInsider · 3 insiders in a week, a first since 2022CEO purchased ~$25K of KTTA shares in the open market

What came next

1. Nov 28, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. Nov 28, 2025Insider · 2 peopleInsiders: 2 purchases (~$125K)
3. Jan 28, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On January 28, 2026, at a Special Meeting of Stockholders (the “Special Meeting”) of Pasithea Therapeutics Corp. (the “Company”), the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2023 Stock Incentive Plan, as amended (the “2023 Incentive Plan”), increasing the number of shares authorized for issuance under the 2023 Incentive Plan by 11,985,779 shares to 14,000,000 shares.”
4. Feb 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pasithea Therapeutics

For Pasithea Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KTTA page.

Other recent filings by Tiago Marques, Chief Executive Officer

• SEC Form 4 at Pasithea Therapeutics (KTTA)May 15, 2025

The full history of Tiago Marques, Chief Executive Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Pasithea Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Jun 22, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Dec 1, 2025
• SEC Form 4Dec 1, 2025
• SEC Form 4May 15, 2025

Everything OQRO holds on this company is on its KTTA page.